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ABSTRACT
Objectives: Determine the real-world difference
between 2 groups of patients with severe aortic
stenosis and similar baseline comorbidities: surgical
turn down (STD) patients, who were managed
medically prior to the availability of transcatheter aortic
valve implantation (TAVI) following formal surgical
outpatient assessment, and patients managed with a
TAVI implant.
Design: Retrospective cohort study from real-world
data.
Setting: Electronic patient letters were searched for
patients with a diagnosis of severe aortic stenosis and
a formal outpatient STD prior to the availability of TAVI
(1999–2009). The second group comprised the first 90
cases of TAVI in South Wales (2009 onwards). 2 years
prior to and 5 years following TAVI/STD were assessed.
Patient data were pseudoanonymised, using the Secure
Anonymized Information Linkage (SAIL) databank, and
extracted from Office National Statistics (ONS), Patient-
Episode Database for Wales (PEDW) and general
practitioner databases.
Population: 90 patients who had undergone TAVI in
South Wales, and 65 STD patients who were medically
managed.
Main outcome measures: Survival, hospital
admission frequency and length of stay, primary care
visits, and cost-effectiveness.
Results: TAVI patients were significantly older (81.8 vs
79.2), more likely to be male (59.1% vs 49.3%),
baseline comorbidities were balanced. Mortality in TAVI
versus STD was 28% vs 70% at 1000 days follow-up.
There were significantly more hospital admissions per
year in the TAVI group prior to TAVI/STD (1.5 (IQR 1.0–
2.4) vs 1.0 IQR (0.5–1.5)). Post TAVI/STD, the TAVI
group had significantly lower hospital admissions (0.3
(IQR 0.0–1.0) vs 1.2 (IQR 0.7–3.0)) and lengths of stay
(0.4 (IQR 0.0–13.8) vs 11.0 (IQR 2.5–28.5), p<0.05).
The incremental cost-effectiveness ratio (ICER) for TAVI
was £10 533 per quality-adjusted life year (QALY).
Conclusions: TAVI patients were more likely to survive
and avoid hospital admissions compared with the
medically managed STD group. The ICER for TAVI was
£10 533 per QALY, making it a cost-effective procedure.
KEY QUESTIONS
What is already known about this subject?
▸ Transcatheter aortic valve implantation (TAVI) is
a transformational, minimally invasive technique
that reduces symptoms, improves quality of life
and decreases mortality for high-risk patients
with severe symptomatic aortic stenosis. While
mortality benefits are well proven, little real-
world long-term data analysis of these groups is
available in terms of survival, admission profiles
and costs.
What does this study add?
▸ This study includes up to 10-year follow-up
(maximum follow-up: 3812 days for medically
managed surgical turn down patients, 1558 days
for TAVI patients) of real-world patients and
tracks all-cause mortality as well as long-term
readmission details using linked anonymised
data. For the first time, we see the direct cost of
both these management strategies together with
a cost-effectiveness analysis.
How might this impact on clinical practice?
▸ While this is a relatively small study, it repre-
sents an important step in real-world long-term
outcomes of either medical therapy or TAVI in a
high-risk population with severe symptomatic
aortic stenosis. It also supports clinical trial
findings of improved outcomes in patients
managed with TAVI and for the first time reveals
that TAVI is a cost-effective procedure in real-
world practice.
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INTRODUCTION
Aortic stenosis is the most common valvular heart
disease which affects 4.6% of adults older than 75 years,
and is associated with signiﬁcant morbidity and mortal-
ity.1 Given the association between age and heart valve
disease, numbers of patients with severe aortic stenosis
are predicted to more than double by 2050 in Europe
and the USA.2 Historically, patients who were deemed to
be at high risk of surgical complication were treated
using medical therapy.
Transcatheter aortic valve implantation (TAVI) is a
transformational, minimally invasive technique that
reduces symptoms, improves quality of life and decreases
mortality for high-risk patients with severe symptomatic
aortic stenosis.3 While mortality beneﬁts are well
proven,4–7 little real-world long-term data analysis of
these groups is available in terms of survival, admission
proﬁles and costs. Brecker et al8 published an analysis of
cost-effectiveness of TAVI versus medical management
(STD) that used a number of data sources (Corevalve
ADVANCE study9 and Partner B4). This study suggested
that TAVI was a highly cost-effective therapy but noted
the limitations of modelling outcomes and costs with
these data in respect of the US context (for cost ana-
lysis).10 We aimed to extend the Brecker et al’s study
using real-world data and outcomes from a single
national data set that was able to capture all readmis-
sions, local costs and outcomes.
In this study, we set out to address these gaps in the lit-
erature by examining routinely collected real-world
national data in Wales to determine the impact of TAVI
on mortality, hospital admissions and cost-effectiveness
in real-life practice.
METHODS
Data sources
We conducted a retrospective cohort analysis using
aortic stenosis registries from the two tertiary cardiac
centres in Wales, linked with secondary care data from
the Patient Episode Database for Wales (PEDW),
primary care data from general practices in Wales and
mortality data from the Ofﬁce of National Statistics
(ONS).
Aortic stenosis registry
Electronic patient letters from University Hospital of
Wales (Cardiff, UK) and Morriston Hospital (Swansea,
UK) were searched for patients with a diagnosis of
severe aortic stenosis and a formal outpatient surgical
turn down (STD) prior to the availability of TAVI (1999–
2009) to generate the medically managed cohort of
patients. The second group was the ﬁrst 90 cases of TAVI
in South Wales (2009 onwards) from both hospitals. The
type of TAVI that was used by University Hospital of
Wales was self-expanding valves (CoreValve) whereas
Morriston Hospital used balloon-expanding valves
(Edwards).
Primary and secondary care data
Data for both cohorts were collected from the primary
care and secondary care database to cover a period of
2 years prior and 5 years following TAVI or STD. These
data included dates and durations of all hospital admis-
sions as well as all visits to see a general practitioner (GP).
Mortality data
These were extracted from the ONS to include date and
cause of death as documented on the ofﬁcial death
certiﬁcate.
Data linkage
These sources of data were pseudoanonymised and
linked using the Secure Anonymized Information
Linkage (SAIL) databank. This databank is a national
Welsh database that links the widest possible range of
person-based data using robust anonymisation techni-
ques.11 12 It contains over 500 million person-based
records and is operated and administered by the Health
Information Research Unit (HIRU), Swansea University,
for the purposes of health-related real-world research.
Outcomes
Our primary outcomes were to determine the difference
in rates of mortality, admission proﬁles and associated
healthcare costs in a real-world setting for two groups of
patients with severe symptomatic aortic stenosis: STD
patients, who were managed medically prior to the avail-
ability of TAVI, and patients managed with a TAVI
implant.
Statistical analysis
Analysis was carried out using SPSS V.19.0 statistics
package (IBM, New York, USA) and Microsoft Excel
(Microsoft, California, USA). The Charlson comorbidity
index was calculated directly from International
Classiﬁcation of Diseases (ICD)-10 diagnoses within the
database using Structure Query Language (SQL) code,
relying on previously described comorbidity scoring
systems as modiﬁed by Bottle and Aylin.13 14
Continuous variables with normal distribution are pre-
sented in tabular form as mean±SD, whereas non-
normally distributed variables are presented as median
with IQR. Patient characteristics were described as fre-
quencies and percentages with χ2 analysis; mortality was
examined using Kaplan-Meier survival analysis and
log-rank testing; and admission proﬁle data, including
Charlson scores, was compared using Student’s t-test for
parametric data or Mann-Whitney U test for
non-parametric data. Signiﬁcance levels were taken at a
p value <0.05.
Economic model
In order to report the economic results of this analysis
as transparently as possible, a simple decision analytic
model was used to assess the long-term cost-effectiveness
of TAVI compared with no treatment. As patient
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mortality data were directly available from the centres
own activity, the primary objective of the model was to
account the potential costs and quality of life outcomes
and quantify the projected values over time.
The computer simulation used was a deterministic
decision analytic tool incorporating a cost-utility element
to evaluate two treatment arms, that is, TAVI and no
intervention. Transition probabilities were derived from
the Kaplan-Meier curves for each arm and used to
account mortality at 30 days, 6 months, 1 year and annu-
ally subsequent to that. The chosen time horizon was
5 years, which is in line with the follow-up data available
for the TAVI arm. The model accounted costs from the
payer perspective (the National Health Service) and
these were limited to the cost of the TAVI intervention
(£22 000 to reﬂect a typically reimbursed UK hospital
payment) and annual costs of readmissions derived from
the original study. For the untreated arm, these were
inﬂated to 2012 values using the hospital and commu-
nity health services index. Quality-adjusted life expect-
ancy measured in quality-adjusted life-years (QALYs) was
quantiﬁed using the published utility values from the
partner B study.4 It was assumed that there were no
changes in quality of life after the ﬁrst year.
All clinical and economic outcomes were discounted
annually at 3.5% in line with UK guidelines. Discounting
is a standard method applied to the projection of future
outcomes that accounts for the biased value of beneﬁts
that occur now versus the future.
RESULTS
There were a total of 90 patients in our data set who had
undergone TAVI and 65 patients who were medically
managed after STD. Maximum (mean) follow-up dur-
ation was 1558 (438) days for TAVI patients and 3812
(728) days for STD patients. Table 1 compares the base-
line characteristics for the two groups. Patients in the
TAVI group were more likely to be older, male, to have a
previous diagnosis of anaemia and to have a higher
Charlson comorbidity index. Other baseline character-
istics were broadly similar between the two groups.
Survival analysis shows that patients who were
managed with TAVI were more likely to survive com-
pared with the STD group (p<0.05) at 3 years follow-up
(ﬁgure 1). Survival rates at 1000 days follow-up were
72% for the TAVI group and 30% for the STD group.
A comparison of the number of hospital admissions
per year for both groups before and after the date of
the TAVI procedure (TAVI group) or STD (STD group)
can be seen in ﬁgure 2. TAVI patients had signiﬁcantly
fewer hospital admissions per year after their procedure
compared with the STD group (0.3 (IQR 0.0–1.0) vs 1.2
(IQR 0.7–3.0), p<0.05), despite the reverse being true
before their procedure (1.5 (IQR 1.0–2.4) vs 1.0 IQR
(0.5–1.5), p<0.05).
Following the procedure/turn-down date, the length
of hospital stay was signiﬁcantly less in the TAVI group
compared with the STD group (0.4 (IQR 0.0–13.8) vs
11.0 (IQR 2.5–28.5), p<0.05), as shown in ﬁgure 3.
There was no signiﬁcant difference in the number of
visits to the GP for either group before and after the
procedure/turn-down date (ﬁgure 4).
A cost-effectiveness analysis can be seen in table 2 and
ﬁgure 5. This demonstrates that the incremental
Figure 1 Kaplan-Meier survival curves comparing the STD
cohort (blue) and TAVI cohort (green). Patients who are lost
to follow-up are censored and are shown as crosses on each
curve (p<0.05). STD, surgical turn down; TAVI, transcatheter
aortic valve implantation.
Table 1 Baseline characteristics
ICD diagnosis STD (n=65) TAVI (n=90)
p
Value
Age 79.2 (±6.59) 81.8 (±7.91) <0.05
Sex (female) 50.70% 40.90% <0.01
Anaemia 11 (20.37%) 29 (36.25%) 0.035
Cancer 7 (12.96%) 17 (21.25%) 0.157
Stroke 4 (7.41%) 11 (13.75%) 0.168
COPD 9 (16.67%) 21 (26.25%) 0.144
Renal failure 11 (20.37%) 9 (11.25%) 0.105
Diabetes 20 (37.04%) 32 (40.00%) 0.736
LVF 32 (59.26%) 54 (67.50%) 0.464
Pulmonary
emboli
2 (3.70%) 2 (2.50%) 0.629
Pulmonary
hypertension
1 (1.85%) 0 (0.00%) 0.174
PVD 5 (9.26%) 12 (15.00%) 0.244
Recent MI 17 (31.48%) 32 (40.00%) 0.314
Charlson index 10.63 (±9.95) 15.81 (±10.46) <0.01
COPD, chronic obstructive pulmonary disease; ICD, International
Classification of Diseases; LVF, left ventricular failure; MI,
myocardial infarction; PVD, peripheral vascular disease; STD,
surgical turn down; TAVI, transcatheter aortic valve implantation.
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cost-effectiveness ratio is £10 533 per QALY gained from
a TAVI procedure.
DISCUSSION
Main findings
This study reveals that patients with severe aortic stenosis
who went on to have TAVI treatment had lower mortality
rates, as well as less frequent and shorter subsequent
hospital admissions than their medically managed
counterparts (STD group). Our data again conﬁrm the
stark prognosis of untreated aortic stenosis with only
30% of patients alive at 1000 days of follow-up.
Moreover, the incremental cost-effectiveness ratio of
£10 533 per QALY gained from undergoing TAVI gives
this procedure a favourable cost–beneﬁt balance.
Strengths and limitations
The most important strength of this study is the use of
real-life individual patient data with linkage of local and
national databases in Wales. This reduces selection bias,
which may accompany carefully selected clinical trial
groups. Additionally, this is the ﬁrst study that examines
the real-life cost-effectiveness of undergoing TAVI using
multiple outcome measures.
Selection of medical cohort (STD following formal
outpatient referral to a consultant cardiothoracic
surgeon) helped identify a cohort that was similar to the
contemporary TAVI population. This has been con-
ﬁrmed by the exploring baseline characteristics. In fact,
on comparing the baseline comorbidities using the
Figure 2 Box plot of frequency of hospital admissions for
the STD and TAVI groups before (blue) and after (green) the
TAVI/turn-down date. Boxes indicate the IQRs with a central
band corresponding to the median, whereas the ‘whiskers’
indicate upper and lower limits. *p<0.05. Mann-Whitney U test
for non-parametric data. NS, not significant; STD, surgical
turn down; TAVI, transcatheter aortic valve implantation.
Figure 3 Box plot of hospital length of stay (in days) for the
STD and TAVI groups before (blue) and after (green) the
TAVI/turn-down date. Boxes indicate the IQRs with a central
band corresponding to the median, whereas the ‘whiskers’
indicate upper and lower limits. *p<0.05. Mann-Whitney U test
for non-parametric data. NS, not significant; STD, surgical
turn down; TAVI, transcatheter aortic valve implantation.
Figure 4 Box plot of frequency of general practice visits for
the STD and TAVI groups before (blue) and after (green) the
TAVI/turn-down date. Boxes indicate the IQRs with a central
band corresponding to the median, whereas the ‘whiskers’
indicate upper and lower limits. Mann-Whitney U test for
non-parametric data. NS, not significant; STD, surgical turn
down; TAVI, transcatheter aortic valve implantation.
Table 2 QALYs and ICER in TAVI and STD patients
TAVI STD Difference
Life-years 3.82 2.09 1.73
QALYs 2.47 1.18 1.29
Costs £44 751 £31 096 £13 655
ICER £10 533/QALY gained
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted
life-year; STD, surgical turn down; TAVI, transcatheter aortic valve
implantation.
4 Freeman PM, Protty MB, Aldalati O, et al. Open Heart 2016;3:e000414. doi:10.1136/openhrt-2016-000414
Open Heart
group.bmj.com on May 30, 2017 - Published by http://openheart.bmj.com/Downloaded from 
Charlson index, the TAVI cohort was signiﬁcantly more
likely to have a higher comorbidity score.
The main limitation to this study is common with
other studies that use retrospective routinely collected
data, which may not have been designed for the pur-
poses of research and audit studies. These limitations
include record keeping issues, which may result in the
potential ‘loss’ of some critical data, due to administra-
tive or data inputting issues. When comparing the base-
line characteristics of groups, there may be hidden
characteristics that are not evident in our data; however,
we have used as many characteristics as possible includ-
ing a full analysis of comorbidity using the Charlson
index variables. Other limitations that need to be consid-
ered include interoperator and interhospital variability
of outcomes and the difference in the type of valve used
by each of the hospitals, with University Hospital of
Wales using self-expanding valves (CoreValve) and
Morriston Hospital using balloon-expanding valves
(Edwards).
Economic modelling
In contrast to other published economic models of
TAVI, there was no distinction between short-term
(30 days) and subsequent clinical events. The details of
perioperative complications such as stroke and bleeding
events were not accounted. Although this may to some
degree alter the actual patient quality of life beneﬁt
due to the difference of TAVI implant performance, the
impact on mortality is fully captured, as are the costs
from the payer perspective.
It is worth noting that the economic model and cost
accounting does not capture primary care costs (GP
visits). It was assumed that these were negligible com-
pared with the costs of rehospitalisations. In addition, it
was assumed that the annual costs of rehospitalisation
did not increase over time. This may be an underestima-
tion of the total costs but given the time horizon
selected and the discounting applied, it was thought that
it would not affect the overall conclusions.
Comparison with other studies
The landmark clinical trial that has demonstrated a mor-
tality beneﬁt with TAVI over medical management in
inoperable patients was the Placement of Aortic
Transcatheter Valves (PARTNER) multicentre trial
(cohort B) which included 358 patients.4–7 The 3-year
survival in that trial was 45.9% in the TAVI (Edwards
balloon-expandable) group and 19.1% in the medically
managed group. Given the mortality beneﬁt that was
demonstrated in the PARTNER trial, it was not possible
to perform clinical trials to directly compare the effects
of self-expanding TAVI (CoreValve) with medically
managed patients, although a prospective single arm
trial using historical controls for comparison demon-
strated a mortality beneﬁt with this type of valve.15
Given the above, and the corroborating data from our
study showing that survival rates in aortic stenosis are
better with TAVI, it should be noted that our real-life sur-
vival rates were markedly better for both groups at 72% for
TAVI and 30% for the medically managed (STD) group.
Additionally, the 3-year mortality rate for TAVI-treated
patients published by the UK TAVI registry studies was
higher (38.8%) than that shown in our study (28%).16
There are no fully published studies that examine the
cost-effectiveness of TAVI compared with medical
management of inoperable patients with severe aortic
stenosis. However, a recent model-based economic evalu-
ation demonstrated that although TAVI is more costly
than medical management, it is more effective, and as a
result, it was associated with an ICER of £12 900 per
QALY, deeming it cost-effective.17 Our current study
demonstrates a real-life ICER of £10 533 per QALY, a
more cost-effective ﬁgure than previous economic
evaluations.
Implications for practice and future research
Despite the limited numbers in this study, there is a
marked improvement in mortality and morbidity rates
that can be seen in patients who undergo TAVI com-
pared with medical management only. Longer follow-up
studies will be interesting to assess long-term outcomes,
which can be derived from routinely collected national
data as was demonstrated by our study.
In conclusion, our results support the use of TAVI
where possible as a cost-effective and clinically effective
intervention in patients with severe aortic stenosis who
are deemed to be at high risk for conventional surgical
valve replacement.
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Figure 5 Incremental bar chart for the costs incurred in the
TAVI and STD populations. Red corresponds to the cost of
procedure (if any), green corresponds to the costs in the first
year after the index date, whereas purple corresponds to
costs in years 2–5.
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